Skip to main content

Stem Cells and Disease Modeling

Our team investigates fundamental mechanisms and translates findings from bench to bedside, combining preclinical models with clinical insight.

Researcher at ICRC with focus on translational medicine. Combines preclinical insights with clinical practice across cardiology, neurology, and oncology programs.

Currently leads / contributes to interdisciplinary projects bridging molecular biology, imaging, and patient care at St. Anne's University Hospital Brno.

Research Group

Team size
Team size: 8 Researchers
Place
Place: Building A1, 3rd Floor
Collaborates with
Collaborates with Charles University, Prague

Head of Research Group

Mgr. Vladimír Rotrekl, Ph.D.
Mgr. Vladimír Rotrekl, Ph.D.
Mgr. Vladimír Rotrekl, Ph.D.

Members

Bc. Tamara Jankovičová

Junior Researcher

Natálie Lungová

Junior Researcher

Mgr. Bc. Deborah Beckerová

Mgr. Bc. Deborah Beckerová

Ph.D. Student

Mgr. Karolína Kocourková

Mgr. Karolína Kocourková

Ph.D. Student

Debora Ledahudcová

Debora Ledahudcová

Research Assistant

Victorio Martin Pozo Devoto, Ph.D.

Postdoctoral Researcher, Principal Investigator

MUDr. Martin Pešl, Ph.D.

MUDr. Martin Pešl, Ph.D.

Senior Postdoctoral Researcher

Mgr. Vladimír Rotrekl, Ph.D.

Mgr. Vladimír Rotrekl, Ph.D.

Senior Research Team Leader

Main Objectives

  1. To determine the extent and mechanisms of heart and cardiovascular progenitors/stem cell depletion in human patients suffering cardiomyopathy with genetic background.
  2. To determine the effect of metabolic, signaling and DNA damage/repair changes on stem cell/progenitor cell fate determination resulting in tissue failure using patient specific/disease specific human pluripotent stem cells.

Research focus

The Stem Cell and Disease Modeling research team (SCDM) builds on long term experience with human pluripotent stem cells, their cultivation and their differentiation.

The current focus of the team aims at the use of human pluripotent stem cells to model human diseases with special foccus on the role of tissue specific progenitors/stem cells on the development of the disease. We foccus on uncovering pathologies in pathways leading to change of cell fate, resulting in tissue failure. We further seek novel strategies to ameliorate the pathological effect on the progenitor/stem cell fate hange. We mostly foccus on processes involven in development of cardiomyopathy and heart failure in monogenic genetic diseases, such as Duchenne Muscular Dystrophy, Catecholinergic Polymorphic Ventricular Tachycardia and also on processes involved in pathological changes of hematpoietic differentiation in genetic diseasaes, such as Nijmegen Breakage Syndrome. Our group uses reprogrammed human patient cells, as well as human embryonic stem cells with edited genome, to create models of monogenic diseases involving cardiomyopathy and pathological hematopoiesis „on the dish“. The team also complements stem cell based modeling with the analysis of both animal models and human patient samples. The SCDM team has also developed novel technology to analyze mechanoelectrical coupling in stem cell derived patients, specifically cardiac syn­cytium based on atomic force microscope.

Technological equipment

  • Reprograming patient specific stem cells; Genome editing of human embryonic stem cells; Biosensor for drug arrhytmogenicity analysis based on coupling human pluripotent stem cell derived cardiomyocytes with atomic force microscope on microelectrode array; Confocal microscopy; Histological analysis. Electrophysiological analysis of excitatory cells.

Selected Results

  • We constructed novel biosensor to deremine arrhytmogenic effect of drugs based on human pluripotent stem cells derived cardiomyocytes (e.g. Klimovic, S et al., Aminophylline Induces Two Types of Arrhythmic Events in Human Pluripotent Stem Cell-Derived Cardiomyocytes. Front Pharmacol. 2022 Jan 17;12:789730. doi: 10.3389/fphar.2021.789730. eCollection 2021. PMID: 35111056)
  • We discovered novel crosstalk between MAPK and PI3K/AKT signaling in pluripotent stem cells (e.g.Fojtík, P et al. Both Hypoxia-Inducible Factor 1 and MAPK Signaling Pathway Attenuate PI3K/AKT via Suppression of Reactive Oxygen Species in Human Pluripotent Stem Cells. Front Cell Dev Biol. 2021 Jan 21;8:607444. doi: 10.3389/fcell.2020.607444. eCollection 2020. PMID: 33553145)
  • We determined novel pathological mechanism leading to cardiomyopathy in Duchenne muscular dystrophy and presented possible therapy (e.g. Jelinkova, S et al., Dystrophin Deficiency Causes Progressive Depletion of Cardiovascular Progenitor Cells in the Heart. Int J Mol Sci. 2021 May 10;22(9):5025. doi: 10.3390/ijms22095025. PMID: 34068508)
  • We discovered novel DNA repair pathway in pluripotent stem cells (e.g. Kohutova, A et al. Ligase 3-mediated end-joining maintains genome stability of human embryonic stem cells. FASEB J. 2019 Jun;33(6):6778-6788. doi: 10.1096/fj.201801877RR. Epub 2019 Feb 26. PMID: 30807703)
  • We discovered novel kinase regulating cell fate of stem cells (e.g. Vanova, T et al. Tyrosine Kinase Expressed in Hepatocellular Carcinoma, TEC, Controls Pluripotency and Early Cell Fate Decisions of Human Pluripotent Stem Cells via Regulation of Fibroblast Growth Factor-2 Secretion. Stem Cells. 2017 Sep;35(9):2050-2059. doi: 10.1002/stem.2660. Epub 2017 Jul 6. PMID: 28631381)